CCO Oncology Podcast

189 Episodo

1. Treatment Options for Patients With Multiple Myeloma After First Relapse

   Publicado: 14/7/2021
2. Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions

   Publicado: 12/7/2021
3. Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas

   Publicado: 12/7/2021
4. Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer

   Publicado: 30/6/2021
5. Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions

   Publicado: 29/6/2021
6. Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

   Publicado: 24/6/2021
7. Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions

   Publicado: 17/6/2021
8. Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer

   Publicado: 19/5/2021
9. Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

   Publicado: 18/5/2021
10. Immunotherapy for Advanced HCC: Case Series

    Publicado: 17/5/2021
11. Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany

    Publicado: 13/5/2021
12. Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond

    Publicado: 4/5/2021
13. Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

    Publicado: 28/4/2021
14. Expert Answers to Questions on Contemporary Management of Multiple Myeloma

    Publicado: 22/4/2021
15. Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates

    Publicado: 19/4/2021
16. Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer

    Publicado: 15/4/2021
17. Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer

    Publicado: 6/4/2021
18. Expert Answers to Questions on PARP Inhibition for Prostate Cancer

    Publicado: 6/4/2021
19. Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

    Publicado: 26/3/2021
20. Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards

    Publicado: 25/3/2021